[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CellCentric Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652457","phase-3-inobrodib-pomalidomide-and-dexamethasone-versus-standard-available-therapy-in-relapsed-or-refractory-multiple-myeloma-100652457",false,"NCT07772024","Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma","A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate Inobrodib in Combination With Pomalidomide and Dexamethasone Versus Standard Available Therapy in Patients With Relapsed or Refractory Multiple Myeloma","DOMMINO-2","Inclusion Criteria:\n\n* Adults aged 18 years or older (or the minimum age of consent under local rules, if that is 18 or over)\n* A diagnosis of multiple myeloma that has either come back (relapsed) or did not respond (refractory) after the most recent treatment\n* Myeloma that can be measured using standard study tests (blood and\u002For urine tests)\n* Between 1 and 4 previous courses (lines) of myeloma treatment, which must have included both a treatment that targets CD38 (such as daratumumab or isatuximab) and lenalidomide\n* Well enough to carry out daily activities with little or no help (Eastern Cooperative Oncology Group \\[ECOG\\] performance status of 0 to 2)\n* Suitable blood test results and adequate kidney and liver function\n* Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners\n\nExclusion Criteria:\n\n* Recent anticancer treatment before starting study treatment: any experimental medicine, chemotherapy, immunotherapy or other anticancer treatment within 14 days or 5 half-lives (whichever is shorter), or certain antibody-based treatments within longer set periods\n* Previous treatment with a medicine that works in the same way as inobrodib (a p300\u002FCBP bromodomain inhibitor)\n* Myeloma that has already stopped responding to pomalidomide (pomalidomide-refractory), unless only short-term pomalidomide was used and the study doctor confirms the person still meets the study rules\n* Unable to receive at least one of the standard treatment options offered in the study, or unable\u002Funwilling to follow the requirements for at least one of those options\n* Taking medicines, herbal supplements or foods (for example, strong CYP3A4 inducers or inhibitors) that would interfere with the study treatment\n* Major surgery within 4 weeks before the first dose of study treatment\n* A live vaccine within 4 weeks before study treatment\n* A recent stem cell transplant, or ongoing transplant-related problems such as graft-versus-host disease\n* Myeloma affecting the brain, spinal fluid or spinal cord, or ongoing pressure on the spinal cord\n* Another active cancer (progressing or needing a change in treatment) in the last 24 months, other than multiple myeloma, apart from certain low-risk or fully treated cancers\n* Serious or uncontrolled medical problems, such as uncontrolled heart, lung, liver, bleeding or diabetes conditions, uncontrolled high blood pressure, or a heart-rhythm problem (including QT prolongation)\n* An active or uncontrolled infection, including certain cases of HIV, hepatitis B or hepatitis C\n* Digestive problems that could stop the study medicines being swallowed or properly absorbed\n* Pregnant or breastfeeding, or planning to become pregnant, father a child or donate sperm during treatment or the required post-treatment period\n* Any illness or medical history that could affect safety, the ability to follow study requirements, or the interpretation of study results","ALL","18 Years",{"count":20,"type":21},450,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The main purpose of this study is to find out whether inobrodib, when given with pomalidomide and dexamethasone, works better than standard treatment for people whose multiple myeloma has come back or has not improved after previous treatment. The study will look at how long people taking part in the study (\"Participants\") live without their myeloma getting worse, and how many people's myeloma improves (responds) following treatment.\n\nThe study will also look at how long participants live overall, how quickly treatment works, how long the response lasts, whether very small amounts of myeloma can still be found after a good response, quality of life, side effects, and the amount of inobrodib in the blood.\n\nParticipants receive treatment in 28-day cycles. One group receives inobrodib by mouth twice a day for 4 days, followed by 3 days without inobrodib each week; pomalidomide by mouth once a day on Days 1 to 21 of each cycle; and dexamethasone once each week.\n\nThe other group receives 1 standard treatment chosen by the study doctor from the following treatment options: daratumumab, pomalidomide, and dexamethasone; elotuzumab, pomalidomide, and dexamethasone; or carfilzomib and dexamethasone. Some standard treatments are given by injection or infusion at the study site. Other medicines, such as tablets or capsules, may be taken by mouth as instructed by the study team.\n\nStudy checks include questions about symptoms and side effects, review of other medicines, physical checks, blood pressure and other vital sign checks, heart tracing tests, blood and urine tests, scans where needed, bone marrow samples, and questionnaires about symptoms and daily life. Participants in the inobrodib group will have extra blood samples to measure the amount of inobrodib in the blood. Some participants may also have extra research blood samples at selected visits.",[27,28],"Multiple Myeloma Refractory","Multiple Myeloma in Relapse",[30,31,32,33,34,35,36],"Inobrodib","Pomalidomide","Pomalyst","Imnovid","Dexamethasone","p300-CBP Transcription Factors","CCS1477","RECRUITING","2026-08-17",{"date":40,"type":41},"2026-08-19","ACTUAL",{"date":43,"type":21},"2026-08",{"date":45,"type":21},"2031-11",{"name":47,"class":48},"CellCentric Ltd.","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100600383","phase-2-inobrodib-pomalidomide-and-dexamethasone-in-relapsed-or-refractory-multiple-myeloma-100600383","NCT07096778","Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","DoMMino-1","Inclusion Criteria:\n\n* Male or female ≥18 years of age\n* Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy\n* Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2\n* Adequate hematological, renal and hepatic function\n* Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners\n\nExclusion Criteria:\n\n* Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days\n* Prior treatment with p300\u002FCBP bromodomain inhibitors\n* Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)\n* Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment\n* Major surgery within 4 weeks of the first dose of study treatment\n* Live vaccine within 4 weeks of study treatment\n* Active or unresolved adverse events\n* Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma\n* Female patients who are pregnant or breast-feeding at any time during the study\n* Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data",{"count":59,"type":21},100,[61],"PHASE2","The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.",[27,28],[30,31,32,33,34,35],"2026-07-29",{"date":67,"type":41},"2026-07-30",{"date":69,"type":41},"2026-01-22",{"date":71,"type":21},"2029-12-01",{"name":47,"class":48},30,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100367769","phase-1-study-to-evaluate-ccs1477-inobrodib-in-haematological-malignancies-100367769","NCT04068597","Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","An Open-label Phase I\u002FIIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.","Inclusion Criteria:\n\n* Provision of consent\n* ECOG performance status 0-2\n* Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)\n* Must have previously received standard therapy\n* Adequate organ function\n\nExclusion Criteria:\n\n* Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose\n* Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment\n* Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment\n* Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment\n* Patients should discontinue statins prior to starting study treatment\n* CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment\n* Any unresolved reversible toxicities from prior therapy \\>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)\n* Any evidence of severe or uncontrolled systemic diseases\n* Any known uncontrolled inter-current illness\n* QTcF prolongation (\\> 470 msec)",{"count":82,"type":21},250,[84,61],"PHASE1","A Phase 1\u002F2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.",[87,88,89,90,91,92],"Haematological Malignancy","Acute Myeloid Leukemia","Non Hodgkin Lymphoma","Multiple Myeloma","Higher-risk Myelodysplastic Syndrome","Peripheral T Cell Lymphoma","2026-06-19",{"date":95,"type":41},"2026-06-24",{"date":97,"type":41},"2019-08-09",{"date":99,"type":21},"2027-03-31",{"name":47,"class":48},39,""]